In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa

Journal of Chemotherapy

Volumn 17, Issue 4, 2005, Pages 355-360

  Piccoli, L ^a   Guerrini, M ^a   Felici, A ^a   Marchetti, Federico ^a  

^a GSK   (Italy)

Author keywords

Amikacin; Ceftazidime; Checkerboard testing; Experimental infections; Levofloxacin; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; CEFTAZIDIME; LEVOFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; GRAM NEGATIVE INFECTION; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 24644454344     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.4.355     Document Type: Article

References (31)

1. Nicastri E, Petrosillo N, Martini L, Larosa M, Gesu GP, Ippolito G, the INF NOS Study Group. Prevalence of nosocomial infections in 15 Italian hospitals: first point prevalence study for the INF-NOS Project. Infection 2003; 31 (Suppl2): 16-22.
2. Blandino G, Marchese A, Ardito F, et al. Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolated in Italy from patients with hospital-acquired infections. Int J Antimicrob Agents 2004; 24:515-518.
3. Bonfiglio G, Carciotto V, Russo G, et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. J Antimicrob Chemother 1999; 41:307-10.
4. Bonfiglio G, Marchetti F. In vitro activity of ceftazidime, cefepime and imipenem on 1005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams. Chemotherapy 2002; 46:229-234.
5. Gesu GP, Marchetti F, Piccoli L, Cavallero A. Levofloxacin and ciprofloxacin in vitro activity on 4003 bacterial clinical isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 2003; 47:816-819.
6. Segatore B, Setacci D, Perilli M, et al. Italian survey on the comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43:428-431.
7. Eliopoulus GM, Eliopoulus CT. Antibiotic combinations: should they be tested? Clin Microbiol Rev 1988; 1:139-156.
8. Neu HC. Synergy and antagonism of combinations with quinolones. Eur J Clin Microbiol Infect Dis 1991; 10:255-261.
9. Gilbert DN, Moellering R, Sande C, eds. The Sanford guide to antimicrobial therapy. Thirty-second edition. Antimicrobial Therapy Inc. VT, USA. 2002.
10. The Medical Letter, Inc. The choice of antibacterial drugs. The Medical Letter on Drugs and Therapeutics 1999; 41:98-104.
11. Bryan LE, Kwan S. Roles of ribosomal binding, membrane potential and electron transport in bacterial uptake of streptomycin and gentamycin. Antimicrob Agents Chemother 1983; 23:835-845.
12. Langtry HD, Lamb HM. Levofloxacin: its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56:487-515.
13. Marchetti F, Viale P. Current and future perspectives of levofloxacin in the treatment of severe Pseudomonas aeruginosa infections. J Chemother 2003; 15:315-322.
14. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med 2005; 171:388-416.
15. Burgess DS, Nathisuwan S. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microb Infect Dis 2002; 44:35-41.
16. Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002; 50:1045-1049.
17. Flynn CM, Johnson DM, Jones RN. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains. J Chemother 1996; 8:411-415.
18. Isemberg H, Alperstein P, France K. In vitro activity of ciprofloxacin, levofloxacin and trovafloxacin alone and in combination with beta-lactams against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkolderia cepacia. Diagn Microbiol Infect Dis 1999; 33:81-86.
19. Pendland SL, Messick CR, Jung R. In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002; 42:75-8.
20. Visalli M, Jacobs M, Appelbaum P. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome and meropenem against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 1998; 42:953-955.
21. Drago L, De Vecchi E, Nicola L, Colombo A, Guerra A, Gismondo MR. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. Chemotherapy 2004; 50:202-210.
22. Craig W. Pharmacokinetic/pharmacodynamic properties of antimicrobial combinations for Gram-negative bacteria. Pharmacotherapy 2001; 21(Suppl.11):337S.
23. Piccoli L, Broggio R, Marchetti F, Di Modugno E. Susceptibility of bacterial respiratory pathogens collected in Italy in 1998-1999 to levofloxacin (LVX) and ciprofloxacin (CIP). 3rd ESCMID International Symposium Nosocomial Infections Today Venice November 5-8, 2000, abstr. 26.
24. Speijer H, Savelkoul PHM, Bonten MJ, Stabberingh EE, Tjhie JHT. Application of Different Genotyping Methods for Pseudomonas aeruginosa in a setting of endemicity in an intensive care unit. J Clin Microbiol 1999; 37:3654-3661.
25. th ed. Approved standard. M7-A4. Villanova, Pa. NCCLS, 1997
26. Eliopoulos GM, Moellering RC Jr. Antimicrobial combinations. In V. Lorian (ed.), Antibiotic in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md. Fourth Edition. 1996; 330-396.
27. O'Reilly T, Cleeland R, Squires EL. Evaluation of antimicrobials in experimental animal infections. In V. Lorian (ed.), Antibiotic in laboratory medicine. Fourth Edition. The Williams & Wilkins Co., Baltimore, Md. 1996; 604-765.
28. Fantin B, Carbon C. In vivo Antibiotic Synergism: Contribution of Animal Models. Antimicrob Agents Chemother 1992; 36:907-912.
29. File TM. Current challenges in the treatment of community-acquired pneumonia. Clin Infect Dis 2004; 38:S1-S4.
30. Cappelletty DM, Rybak MJ Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40:677-683.
31. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25:485-506.